{"id":355001,"date":"2026-01-30T00:00:00","date_gmt":"2026-01-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2024-biopharma-acute-myeloid-leukemia-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:34","modified_gmt":"2026-03-31T10:23:34","slug":"dlsfon0016-2026-biopharma-acute-myeloid-leukemia-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2026-biopharma-acute-myeloid-leukemia-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Acute Myeloid Leukemia &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Acute myeloid leukemia (<abbr title=\"acute myeloid leukemia\">AML<\/abbr>) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of <abbr title=\"acute myeloid leukemia\">AML<\/abbr> treatment, the recent approval of new drugs, such as Revuforj (revumenib), Komzifti (ziftomenib), and Vanflyta (a second-generation <abbr data-abbreviation-entity=\"7629\" title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr> inhibitor), indicates a trend toward more-targeted therapies. Moreover, both early- and late-phase pipelines for <abbr title=\"acute myeloid leukemia\">AML<\/abbr> include various drug classes such as menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies. Despite the recent failures of several drugs in late-phase development, we expect the expansion of existing therapies into additional patient populations and the approval of new treatments to lead to notable growth in the <abbr title=\"acute myeloid leukemia\">AML<\/abbr> drug therapy market.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large are the clinically and commercially relevant drug-treatable <abbr title=\"acute myeloid leukemia\">AML<\/abbr> populations, and how will drug-treatable rates change (if at all) over the 2024-2034 forecast period?<\/li>\n<li>What is the current treatment landscape for <abbr title=\"acute myeloid leukemia\">AML<\/abbr>? What are the key takeaways from expert interviews?<\/li>\n<li>What are the most promising therapies in the pipeline, and how will they influence the <abbr title=\"acute myeloid leukemia\">AML<\/abbr> therapy market in the future?<\/li>\n<li>What are the primary factors driving and limiting the <abbr title=\"acute myeloid leukemia\">AML<\/abbr> market, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan.<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incidence of <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> by country, clinically and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"acute myeloid leukemia\">AML<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-355001","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/355001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":6,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/355001\/revisions"}],"predecessor-version":[{"id":575211,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/355001\/revisions\/575211"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=355001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}